Sensus Healthcare (NASDAQ:SRTS) Cut to “Strong Sell” at Zacks Research

Zacks Research downgraded shares of Sensus Healthcare (NASDAQ:SRTS) from a hold rating to a strong sell rating in a research note issued to investors on Tuesday,Zacks.com reports.

A number of other brokerages have also issued reports on SRTS. Wall Street Zen lowered shares of Sensus Healthcare from a “hold” rating to a “sell” rating in a research report on Sunday, June 22nd. HC Wainwright dropped their price objective on shares of Sensus Healthcare from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, August 12th. Finally, Lake Street Capital reduced their price objective on shares of Sensus Healthcare from $13.00 to $6.00 and set a “buy” rating for the company in a report on Friday, August 8th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Sensus Healthcare presently has an average rating of “Moderate Buy” and a consensus price target of $8.00.

Sensus Healthcare Trading Down 0.9%

Shares of SRTS stock opened at $3.13 on Tuesday. Sensus Healthcare has a 1 year low of $3.03 and a 1 year high of $9.33. The firm’s fifty day simple moving average is $3.83 and its 200 day simple moving average is $4.37. The firm has a market capitalization of $51.46 million, a P/E ratio of -52.17 and a beta of 1.41.

Sensus Healthcare (NASDAQ:SRTS) last announced its earnings results on Thursday, August 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.07). Sensus Healthcare had a negative return on equity of 1.58% and a negative net margin of 2.26%.The company had revenue of $7.32 million for the quarter, compared to the consensus estimate of $9.30 million. Equities research analysts anticipate that Sensus Healthcare will post 0.32 EPS for the current fiscal year.

Institutional Investors Weigh In On Sensus Healthcare

Institutional investors and hedge funds have recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Sensus Healthcare in the 1st quarter valued at $71,000. Millennium Management LLC boosted its stake in shares of Sensus Healthcare by 256.6% in the 4th quarter. Millennium Management LLC now owns 85,329 shares of the company’s stock valued at $590,000 after purchasing an additional 61,403 shares in the last quarter. IFP Advisors Inc boosted its stake in shares of Sensus Healthcare by 37.2% in the 1st quarter. IFP Advisors Inc now owns 18,800 shares of the company’s stock valued at $89,000 after purchasing an additional 5,100 shares in the last quarter. Pacific Ridge Capital Partners LLC acquired a new stake in shares of Sensus Healthcare in the 1st quarter valued at $542,000. Finally, Bank of New York Mellon Corp boosted its stake in shares of Sensus Healthcare by 3.9% in the 1st quarter. Bank of New York Mellon Corp now owns 141,971 shares of the company’s stock valued at $672,000 after purchasing an additional 5,289 shares in the last quarter. Institutional investors and hedge funds own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.